
Scottish health minister admits 'influence' on chronic pain research
Minto says there was no intention to 'minimise or undermine' patient experiences. But The Herald has uncovered a Government official dictating in advance to researchers the levels Government sought of pain causing little and even no impact on activities. Campaigners now want all health research checked for interference.
For over two years, there's been secrecy over this Pain Management report, while NHS clinics dealing with serious pain are being discussed in private by the same officials in a Government 'Task Force'.
Read more: Hundreds of Scottish pain patients dying in agony in NHS queues (add link)
Health Secretary Neil Gray and John Paul Marks, head of Scotland's civil service wouldn't even reply to letters from MSPs Miles Briggs and Monica Lennon. Minto herself acknowledged complaints but excluded answers on the report until now. Secrecy meant Freedom of Information had to be used to discover officials had replaced authenticated volunteers with people paid £200 each, commercially recruited.
But what amounts to shambolic and ignorant Government interference in health research is now shown in a letter by Minto to Labour's Rhoda Grant MSP who persisted, like the SNP's Fergus Ewing, Conservative Miles Briggs and Holyrood's Cross Party Group on Chronic Pain, in pushing for truth.
Now, the public health minister:
Admits the term 'no impact' for three patients was 'Proposed by the Scottish Government – participant patients did not use the term no impact themselves'.
Admits that 16 people 'were not asked if they were diagnosed by a health professional' But this was not revealed.
Admits Govt included three of the self-diagnosed who also self-medicated from the internet.
Admits the Scottish Government sought people who 'self-reported chronic pain but did not experience any impact on their activities'.
Ministers and officials in charge of Scotland's health clearly did not know that three learned bodies state that 'no impact is not a recognised category with chronic pain'
'Chronic pain does not exist without having any impact. - sufferers have to make life choices, changes, compromises." states the Faculty of Pain Medicine of the Royal College of Anaesthetists.
An email shows private researchers, The Lines Between, had told Clinical Priorities they couldn't find any with no impact'. But an official insisted the researchers persist, saying 'We are still very keen to recruit from this group', urging the Lines Between to try their recruitment firm again (which uses social media)Three were later classed no impact, ludicrously in the case of an Inverness woman, quoted in the report stating she was on pain relief from her GP and 'had severe migraines and sciatica and could hardly walk'. She was marked 'no impact'. Two others, also from Inverness, were also marked 'no impact' without explanation.
Ms Minto now admits that no impact meant only at time of being asked on the patient panel. Minto added: 'It did not mean that they had never experienced any impact from their chronic pain'. But the report doesn't say that. This is an extraordinary statement from anyone in charge of health and lives. We don't know if patients were aware how impact was classed on the day. Although not officially diagnosed, they do describe real suffering especially those at high level.
The small numbers suffering at high level produced under Clinical Priorities officials contrast with many other reports.
Public Health Scotland surveyed 92 chronic pain patients in 2022, finding 82% reported high suffering, 16% a little. They found 'only one person in 92 said their chronic pain does not limit their activities'
That contrasts with three out of 16 claimed to have no impact, seven little and only six out of 16 in serious pain, in the Government officials' handling.
Minto now says, over two years later, it was a mistake to use no impact without explanation, adding: 'The wording no impact that we chose has clearly created the unintended impression that experiences shared by some participants were being undermined or minimised'.
But suffering levels were dictated and minimised ahead of the report. An FOI-released email to the Parliament's cross party group showed a senior official at the Clinical Priorities Unit dictated patient numbers and suffering levels to researchers in August 2022, long before November publication. The report is still circulating in connection with a new pain 'Framework' where the same Unit's officials are also recommending on patients' future services.
Suffering 'a lot' was to be in the minority compared with a combination of little and no impact. A name-redacted Clinical Priorities official wrote to private researchers in advance asking them to 'adjust the quotas/targets on impact' on numbers suffering to:
'A lot' – 7
'A little' – 11 – 12
- 'Not at all' – 2 – 3 (also called no impact)
The finished Government report showed only six high impact, seven little impact and three no impact.
Former health secretary Alex Neil said he was appalled and called for an independent probe into health work, saying of Govt interference: 'This is shocking. You don't do this to research in advance. It's totally dishonest. Anyone from Government suggesting such sharp practices should be disciplined. There should be a complete clear out and new people brought in who can be trusted.'
When he was health secretary, he 'would have sent back anything if it was manipulated like that'.
Clinical Priorities officials already recommend policy on nine major issues – long covid, stroke, diabetes, respiratory conditions, heart disease, endometriosis, out of hospital cardiac arrest, neurological conditions, chronic pain.
Read more: The sorry tale of Scotland's chronic pain crisis
Professor Lindsay Paterson of Edinburgh University's School of Social and Political Science thought the situation 'very disturbing'. He is not involved with chronic pain, 'but all this is similar to what has been noted in other connections, such as sex and gender' – a reference to pressure from government-paid groups in the trans controversy. Prof Paterson declared the need for urgent investigation on wider influence, stating:
"There is a real problem in Scottish policy research that the people who commission it are sometimes unhealthily close to the researchers who do it. This can compromise the independence of researchers and the objectivity of research reports. To assess the extent of the problem, and point to ways forward, the Scottish Parliament should commission a report from a distinguished researcher based outside Scotland who has not recently had any research funding from the Scottish Government."
Professor Lindsay Paterson of Edinburgh University's School of Social and Political Science called the situation 'very disturbing' (Image: Edinburgh University) Although a private firm was used on pain, Prof Paterson also wanted universities to be more protected. 'If a researcher is under pressure from their university or other employer to take the money, even with the possibility of Government interference, then the researcher should say that in public, so there is wider public debate on what is happening.'
On The Herald expose, he remarked: 'This confirms the importance of researchers refusing to give in to pressure from the Scottish Government. That must mean they should insist on this in the contract.'
Some treatment cuts have already happened under a Nicola Sturgeon policy, still pursued. Sturgeon wrote in Sept 2020 she wanted to 'reduce reliance' on NHS specialist pain clinics for out patients and increase self-management. Patients protested this was false economy, claiming that withdrawing key treatments would increase costs and GP and emergency work.
Conflict of interest
But Jenni Minto is now set to let the Clinical Priorities Unit, now renamed the Long Term Conditions Policy Unit, tackle an even bigger project, increasing their influence on health.
Chronic pain has around 800,00 Scottish sufferers, all long term conditions are estimated at over a million to 1.5 million in Scotland. There's to be yet another Consultation, so far with the same unit. Although renamed, they have the same Unit head, Will Wood and mostly the same staff. Wood wrote last year to the voluntary cross party group refusing to answer questions on the report. He is also deputy chair of the Pain Management Task Force recommending to ministers on patients' future treatments.
Using the same Unit to commission and supervise research and also recommend on patients' future treatments is a major patient concern, which the pain group calls 'direct conflict of interest and surely against Human Rights protections on disability'.
Minto was informed by patients at a March 12 meeting, that they did not want this Unit involved again in any capacity. Ian Semmons, the disabled founder of Action on Pain, a leading UK Charity, says the way pain suffering is treated by the Scottish Government is the worst he's encountered in the UK and Europe.
Read more: Revealed: Hidden scandal of chronic pain wait times
He wants an urgent investigation into health handling at the top.
'In over 30 years of chairing our charity, my journey has taken me across these islands and well beyond. Our charity's experience and knowledge have been valued and helped shape some services in the world. The Scottish Government stands in shocking contrast to all I've dealt with in the way it ignores patients. The behaviour of its official team beggars belief.' He volunteered for a previous SG advisory group he called 'another sham'.
'The constant barriers of delay, deceit, intimidation and bullying mixed with sheer arrogance left me angered and in despair.
I've no axe to grind I wanted to help patients, but patients are treated like outcasts by this Government. People must be held to account, as they've all clearly demonstrated why they should no longer be in their roles.'
The Government's £19 billion health and care budget has given no extra money to NHS hospital pain clinics.
Government officials didn't inform voluntary patients with known conditions that they sought a 'patient panel'. Commercial recruiters were told to exclude 'patient advocates' and those with prior knowledge of Government groups, claiming only 'little heard' people were sought. Such a diktat deprives patients of anyone with knowledge on their side.
The report was signed off by former public health minister Maree Todd, now minister for social care, mental health and sport. But her successor Jenni Minto has long defended the report. Todd's original welcome of the report is now removed online.
A new Consultation on almost all long-term conditions was proposed in October 2024, but no clear information since. Jenni Minto has so far relied on the same officials patients want changed urgently.
Patients have had no details and fear yet another consultation will mean no action on shortages until 2026 election time or after.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


BBC News
an hour ago
- BBC News
Royal Berkshire Hospital's share of £4.4m funding 'not enough'
Funding awarded to a hospital for repairs and refurbishments is "not enough", a local MP has said. The government announced a £4.4m shared grant for Royal Berkshire Hospital (RBH) and Bracknell Liberal Democrat MP for Wokingham Clive Jones said the cash would "not touch the sides".The government said the funding would prevent appointments being cancelled and blamed "14 years of austerity" from previous administrations for the current problems in the NHS. The hospital, on Craven Road in Reading, was set to be rebuilt under the last government's new hospitals this has been delayed until at least 2037 by the current government, which said the previous plan was not affordable. Jones said the money was "very welcome" but "not enough"."We have £102m shortfall already and it's forecast to be up to £400m in the next 10 to 15 years," he said."So, £4.4m really does not touch the sides."He said he had met with Minister of State for Health Karen Smyth about the matter."Even if they give us £4.4m every year for the next 10 years we've still got a significant shortfall," he continued."I know the minister is well aware of the special circumstances of the Royal Berkshire and that there are parts of it that are 200 years old."Chief executive of RBH Steve McManus said he had also hoped for more funding. He said: "The hospital was in a losing battle against a constant need for repairs, with 50 operations being cancelled in 18 months due to estate disrepair, including power cuts, leaking roofs and collapsed ceilings."A spokesperson from the Department of Health and Social Care said: "We inherited a crumbling NHS following 14 years of austerity, including during the Lib Dems' time in office, but we are determined to turn this around."This week's investment is an essential step to make our hospitals safer and more efficient places to provide care."It added: "These works are funded through the Budget, which provided an extra £26 billion for health and care, and was voted against by the Lib Dems along with every other opposition party. Only Labour will rebuild our broken NHS." You can follow BBC Berkshire on Facebook, X (Twitter), or Instagram.


North Wales Chronicle
an hour ago
- North Wales Chronicle
Alzheimer's blood test ‘can accurately pick up early symptoms'
Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'


South Wales Guardian
an hour ago
- South Wales Guardian
Alzheimer's blood test ‘can accurately pick up early symptoms'
Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'